• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab: COMMENT from Eşkazan et al.

作者信息

Aydın Tahacan, Elverdi Tuğrul, Özer Çerme Melis Dila, Eşkazan Ahmet Emre

机构信息

Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.

Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.

出版信息

J Thromb Haemost. 2021 Oct;19(10):2644-2646. doi: 10.1111/jth.15495.

DOI:10.1111/jth.15495
PMID:34558784
Abstract
摘要

相似文献

1
Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab: COMMENT from Eşkazan et al.用卡泊单抗治疗的免疫性血栓性血小板减少性紫癜颅内出血：埃什卡赞等人的评论
J Thromb Haemost. 2021 Oct;19(10):2644-2646. doi: 10.1111/jth.15495.
2
Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab.接受卡泊单抗治疗的免疫性血栓性血小板减少性紫癜患者的颅内出血
J Thromb Haemost. 2021 Aug;19(8):1922-1925. doi: 10.1111/jth.15363. Epub 2021 Jun 9.
3
Five years of caplacizumab - lessons learned and remaining controversies in immune-mediated thrombotic thrombocytopenic purpura.卡普拉珠单抗治疗免疫性血栓性血小板减少性紫癜 5 年：经验与争议
J Thromb Haemost. 2023 Oct;21(10):2718-2725. doi: 10.1016/j.jtha.2023.07.027. Epub 2023 Aug 9.
4
Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura?卡普雷珠单抗：在妊娠相关免疫性血栓性血小板减少性紫癜中也是改变游戏规则的药物？
Br J Haematol. 2023 Aug;202(4):725-727. doi: 10.1111/bjh.18915. Epub 2023 Jun 8.
5
Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment.卡普拉西珠单抗：血栓性血小板减少性紫癜治疗模式的改变。
Expert Opin Biol Ther. 2019 Nov;19(11):1127-1134. doi: 10.1080/14712598.2019.1650908. Epub 2019 Aug 5.
6
Safety and efficacy of caplacizumab retreatment in a real-life monocentric cohort of patients with immune-mediated thrombotic thrombocytopenic purpura.卡泊珠单抗再治疗在免疫性血栓性血小板减少性紫癜真实单中心队列患者中的安全性和有效性
Thromb Res. 2023 Aug;228:189-190. doi: 10.1016/j.thromres.2023.06.018. Epub 2023 Jun 16.
7
Von Willebrand factor assays in patients with acquired immune thrombotic thrombocytopenia purpura treated with caplacizumab.在接受卡普拉西珠单抗治疗的获得性免疫性血栓性血小板减少性紫癜患者中进行 von Willebrand 因子检测。
Br J Haematol. 2022 May;197(3):349-358. doi: 10.1111/bjh.18080. Epub 2022 Mar 8.
8
Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.卡普雷珠单抗可降低获得性血栓性血小板减少性紫癜患者的主要血栓栓塞事件、恶化事件和死亡的发生频率。
J Thromb Haemost. 2017 Jul;15(7):1448-1452. doi: 10.1111/jth.13716. Epub 2017 Jun 5.
9
Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?所有免疫介导的血栓性血小板减少性紫癜患者都应该接受卡普西单抗治疗吗？
J Thromb Haemost. 2021 Jan;19(1):58-67. doi: 10.1111/jth.15194. Epub 2020 Dec 17.
10
Illustrated treatment of refractory immune thrombotic thrombocytopenic purpura with caplacizumab.卡泊单抗治疗难治性免疫性血栓性血小板减少性紫癜的图示治疗方法。
BMJ Case Rep. 2021 Aug 9;14(8):e245600. doi: 10.1136/bcr-2021-245600.

引用本文的文献

1
Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project).卡泊单抗在免疫介导的血栓性血小板减少性紫癜中的应用：一项国际多中心回顾性队列研究（Capla 1000+项目）
EClinicalMedicine. 2025 Mar 30;82:103168. doi: 10.1016/j.eclinm.2025.103168. eCollection 2025 Apr.
2
Does Caplacizumab for the management of thrombotic thrombocytopenic purpura increase the risk of relapse, exacerbation, and bleeding? An updated systematic review and meta-analysis based on revised criteria by the International Working Group for thrombotic thrombocytopenic purpura.卡泊单抗用于治疗血栓性血小板减少性紫癜会增加复发、病情加重和出血的风险吗？基于血栓性血小板减少性紫癜国际工作组修订标准的最新系统评价和荟萃分析。
EJHaem. 2023 Dec 18;5(1):178-190. doi: 10.1002/jha2.833. eCollection 2024 Feb.